A small molecule E-selectin inhibitor (uproleselan), in combination with chemotherapy, has completed phase 1 and phase 2 clinical trials in AML, demonstrating safety and early evidence of efficacy, and is being explored in an ongoing pivotal phase 3 trial25,27. The gene discussed is SELE; the disease is acute myeloid leukemia.